Compare TPC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | GRFS |
|---|---|---|
| Founded | 1894 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | 2003 | 2008 |
| Metric | TPC | GRFS |
|---|---|---|
| Price | $88.21 | $7.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $86.00 | $10.15 |
| AVG Volume (30 Days) | ★ 455.2K | 344.9K |
| Earning Date | 05-06-2026 | 07-28-2022 |
| Dividend Yield | 0.28% | ★ 1.80% |
| EPS Growth | ★ 148.24 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $5,543,039,000.00 | N/A |
| Revenue This Year | $15.37 | $4.49 |
| Revenue Next Year | $9.99 | $6.42 |
| P/E Ratio | $51.38 | ★ $18.67 |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $57.90 | $6.96 |
| 52 Week High | $102.30 | $10.23 |
| Indicator | TPC | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 50.88 |
| Support Level | $86.39 | $7.66 |
| Resistance Level | $88.28 | $8.36 |
| Average True Range (ATR) | 3.19 | 0.18 |
| MACD | -0.93 | -0.03 |
| Stochastic Oscillator | 14.72 | 28.64 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.